Alison Kodjak
-
A former official in the civil rights office says the unit seems afraid to offend U.S. Customs and Border Protection and ICE. Meanwhile, the complaints of abuses of families continue to pile up. -
Certain high-cost drugs are straining state budgets. A new deal approved Wednesday allows Louisiana to spend a fixed amount for unlimited access to a costly cure. Other states may try to follow suit. -
A quirk in the law gives an older opioid addiction treatment "orphan drug" status — and a period of exclusive market access. That may prevent some new therapies from reaching patients for years. -
The Senate Finance Committee will hear Tuesday from executives from the biggest pharmacy benefit managers. Confidential rebates paid to the PBMs are expected to draw scrutiny. -
Lawmakers in the House and Senate are pressing companies to lower prices for insulin which is essential for many people with diabetes. The price is 10 times higher today than it was 20 years ago.
-
A federal judge has struck down a Medicaid work requirement in Arkansas and Kentucky. This is a major blow to the Trump administration's vision for the health insurance program for low-income people.
-
The Trump administration wants to increase transparency in prescription drug pricing. But health economists say the administration's call to tie prices to what other nations pay might work better. -
A little-noticed Trump administration proposal would require hospitals, doctors and insurers to post the true, negotiated price for a medical procedure or service, as opposed to the "list" price. -
In a surprise move, the Food and Drug Administration commissioner announced Tuesday he will resign from his position. Dr. Scott Gottlieb is widely viewed as an effective advocate of public health.
-
A new poll by the Kaiser Family Foundation shows that many people struggle to pay for medicines and that a majority of Americans would welcome a range of government interventions to lower prices.
